Forte Pharma, Reig Jofre’s nutritional supplements line, enters in Hong Kong and Macao
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
Forte Pharma, Reig Jofre’s nutritional supplements line, has recently entered Hong Kong and Macao through RS Lifestyle, a local partner, leader in the distribution of consumer products.
Watson’s drugstores, with more than 200 stores all around Hong Kong and Macao, has been the entry door for Forte Pharma in these markets, where the company has launched Vitality 4 from the energy range; and Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg from slimming range.
Vitality 4, Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg are among the top five products in Forte Pharma sales, and the first three with more than 10 years of recognized market position in its category. Turboslim Fat Redux was launched in 2014.
Following its integration in the pharmaceutical company Reig Jofre, Forte Pharma designed an expansion plan into new markets through agreements with local distributors. As a result of this strategy, in 2015 Forte Pharma initiated contacts in a dozen markets in Europe and Asia, which allowed as first achievement to formalize the entry into Hong Kong and Macao in the first months of 2016.
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
At present, marketing of Forte Pharma products is done mostly in Europe through its own sales network. In the coming years the company estimates a potential significant growth in markets where Forte Pharma is not yet present.
Forté Pharma products are organized into four ranges: slimming (54% of its total sales), energy (18%), beauty (17%) and health (11%). Revenues from the area of nutritional supplements and consumer healthcare, to which Forte Pharma belongs, amounted to 35 million euros in 2015, 22% of Reig Jofre total turnover, with a growth of 3% compared to 2014.
François Gaydier, Forte Pharma’s General Manager, said: "We hope that the entry into Hong Kong will help us to lay a solid foundation for further growth in the future via distribution agreements, since our goal is to launch other products in this market in the short term and expand our brand in other Asian countries."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance